Please login to the form below

Not currently logged in
Email:
Password:

palbociclib

This page shows the latest palbociclib news and features for those working in and with pharma, biotech and healthcare.

Novartis claims a rare win at ESMO for PI3K inhibitor class

Novartis claims a rare win at ESMO for PI3K inhibitor class

6 inhibitor, a newer drug group which includes Novartis’ own Kisqali (ribociclib), Pfizer’s Ibrance (palbociclib) and Eli Lilly’s Verzenio (abemaciclib).

Latest news

More from news
Approximately 7 fully matching, plus 45 partially matching documents found.

Latest Intelligence

  • Engaging the digital healthcare professional Engaging the digital healthcare professional

    When NICE, the UK policymaker for health spending, rejected Pfizer’s breast cancer drug palbociclib for routine funding on the NHS in February, it tweeted the news and invited comments on ... Weeks later, following the NICE consultation period, the

  • Pharma deals during August 2013 Pharma deals during August 2013

    Palbociclib, which is the result of an early partnership with Pfizer and now being developed by Pfizer, is in phase III trials for advanced breast cancer and certain haematologic malignancies. ... If approved, Onyx will receive an 8 per cent royalty on

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Synergy Vision

    Pfizer have recently announced that they will provide the breast cancer drug, palbociclib, free of charge to patients.

  • Pharma and free medicines: a different perspective

    The cost of a full course of treatment with palbociclib is approximately £80, 000. ... Therefore, it will be interesting to see the final ruling of NICE on palbociclib. .

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics